The ROS1 inhibitor entrectinib has been listed on the PBS for the treatment of patients with ROS-1 positive NSCLC. From 1 August, Roche’s entrectinib will be subsidised for patients with locally advanced (Stage IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) patients with a c-ROS proto-oncogene 1 (ROS1) gene rearrangement. Treatment eligibility is ...
PBS listing for ROS-1 positive NSCLC therapy
By Michael Woodhead
4 Aug 2020